Ovarian Cancer: Challenges in Diagnostic Innovation
Most women will never be screened for ovarian cancer. Unlike with breast and cervical cancers, ovarian cancer research has struggled…
Women Make Up 72% of Study Participants for FDA-Approved New Drugs in 2019
SWHR is thrilled with the news that women accounted for 72% of all clinical trial participants for FDA-approved new drugs…
The Promise and Peril of AI in Women’s Health
Artificial intelligence has great potential to transform health care for women if we can mitigate AI's tendency for propagating biases…
Ovarian Cancer: Outdated Diagnostics for a Deadly Disease
Over 20,000 women will be diagnosed with ovarian cancer this year in the United States, and less than half of…
Advancing Women’s Health Requires the Study of Sex and Gender Differences
Women’s Health Research Day celebrates the day that NIH’s policy requiring inclusion of sex as a biological variable in research…
SWHR Launches Search for CEO in 2020
SWHR CEO Amy M. Miller announces that she is leaving in 2020 and SWHR begins search for new leader.
No ‘Best’ Framework for Assessing Value of Health Care Innovations, NPC Report Says
A report from the National Pharmaceutical Council (NPC) concludes that there is no “best” framework for determining the value of…
A Call to Improve Suicide Prevention for Women Veterans
Women veterans are two times more likely than non-veteran women to die by suicide, and there is a dire need…
SWHR Remembers Former Board Member Dr. Bruce McEwen
SWHR remembers former SWHR Board member Bruce McEwen, PhD, who passed away on January 2, 2020.